The Fort Worth Press - Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

USD -
AED 3.672502
AFN 64.501933
ALL 82.250493
AMD 360.509682
ANG 1.790403
AOA 917.9999
ARS 1552.25002
AUD 1.484485
AWG 1.8
AZN 1.720974
BAM 1.779545
BBD 2.01413
BDT 124.905034
BGN 1.77347
BHD 0.377199
BIF 3005
BMD 1
BND 1.288858
BOB 11.66537
BRL 5.778798
BSD 1.000059
BTN 93.425596
BWP 13.998644
BYN 3.001178
BYR 19600
BZD 2.011401
CAD 1.430405
CDF 2294.000218
CHF 0.84154
CLF 0.025264
CLP 994.320045
CNY 6.66615
CNH 6.66784
COP 3309.02
CRC 445.481718
CUC 1
CUP 24.000873
CVE 100.450625
CZK 22.18055
DJF 177.71961
DKK 6.80228
DOP 60.449916
DZD 137.107748
EGP 53.721899
ERN 15
ETB 161.349747
EUR 0.91008
FJD 2.297896
FKP 0.758367
GBP 0.757515
GEL 2.58991
GGP 0.758367
GHS 11.739719
GIP 0.758367
GMD 73.999789
GNF 8860.000445
GTQ 7.643069
GYD 209.144677
HKD 7.84612
HNL 27.079751
HRK 6.831965
HTG 131.024035
HUF 333.576498
IDR 18255
ILS 3.254645
IMP 0.758367
INR 93.47505
IQD 1515
IRR 1929053.503699
ISK 124.501955
JEP 0.758367
JMD 158.919789
JOD 0.708984
JPY 159.550501
KES 129.940392
KGS 87.449006
KHR 4075.00003
KMF 448.000286
KPW 900.00035
KRW 1331.634967
KWD 0.31169
KYD 0.833458
KZT 444.016797
LAK 22537.510656
LBP 89549.999942
LKR 332.782835
LRD 168.749976
LSL 16.939855
LTL 2.95274
LVL 0.60489
LYD 6.454983
MAD 9.96875
MDL 18.311519
MGA 4590.000303
MKD 55.966536
MMK 2099.8229
MNT 3605.49036
MOP 8.082545
MRU 40.654979
MUR 47.860367
MVR 15.373613
MWK 1736.00024
MXN 18.421204
MYR 4.093598
MZN 63.897729
NAD 16.940103
NGN 1351.390091
NIO 36.770187
NOK 9.631685
NPR 149.481136
NZD 1.81973
OMR 0.384495
PAB 1.000032
PEN 3.415038
PGK 4.49375
PHP 63.658503
PKR 276.505202
PLN 4.00607
PYG 6230.864068
QAR 3.6453
RON 4.867699
RSD 107.049842
RUB 82.200016
RWF 1476
SAR 3.756442
SBD 8.137041
SCR 13.817596
SDG 601.503198
SEK 10.13279
SGD 1.288805
SHP 0.757117
SLE 22.808796
SLL 20969.503664
SOS 572.506901
SRD 37.438014
STD 20697.981008
STN 22.65
SVC 8.750364
SYP 13002.000337
SZL 16.940433
THB 33.8265
TJS 9.216015
TMT 3.5
TND 3.042499
TOP 2.40776
TRY 50.4403
TTD 6.771395
TWD 32.924978
TZS 2649.998027
UAH 45.33545
UGX 4149.985442
UYU 40.627659
UZS 12029.999909
VES 915.501898
VND 25712.5
VUV 120.845902
WST 2.802705
XAF 596.973424
XAG 0.021128
XAU 0.000260312271
XCD 2.70255
XCG 1.802383
XDR 0.707052
XOF 596.973424
XPF 108.874951
YER 236.550291
ZAR 16.926805
ZMK 9001.200097
ZMW 20.486504
ZWL 321.999592
SSP 5946.953244
MXV 2.066571
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

Canalevia®-CA1, Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea in dogs, has received extension of conditional approval by FDA

Jaguar is attending the December 3-5 Pet Connect conference and is available for NP300 partnership discussions at the event

Text size:

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

Canalevia®-CA1, Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea in dogs, has received extension of conditional approval by FDA

Jaguar is attending the December 3-5 Pet Connect conference and is available for NP300 partnership discussions at the event

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced that it is seeking a partner to fund and execute the development and commercialization of NP300, the company's prescription drug candidate for the treatment of general, non-infectious diarrhea in dogs, in exchange for commercial rights to the product in the U.S.

NP300 is a novel antisecretory drug with a similar mechanism of action to Canalevia®-CA1 (crofelemer delayed-release tablets), the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. NP300 has demonstrated safety in dogs and is sustainably derived from the Croton lechleri tree, the same source as that for crofelemer.

"We look forward to evaluating NP300 for treatment of general, non-infectious diarrhea in dogs, and to identifying a partner organization to fund and execute development and commercialization of the product," said David Sesin, PhD, Jaguar's Chief Manufacturing Officer. "We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet need for a product to treat general, non-infectious diarrhea in dogs as well. We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs. We are attending the Pet Connect conference, which takes place December 3-5, 2024 in Hollywood, California, with the goal of speaking with potential partners about NP300."

Diarrhea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drug to treat canine diarrhea. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of U.S. households owning a dog in 2024. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of control in urban settings where owners don't have easy access to outdoor facilities is a significant problem for families with dogs.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Important Safety Information About Canalevia-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that company personnel will attend the December 3-5, 2024 Pet Connect conference, and Jaguar's expectation that it may identify a partner organization to fund and execute development and commercialization of NP300. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.

Contact:

[email protected]
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

C.Dean--TFWP